Metformin and Its Benefits for Various Diseases.
Lv Z, Guo Y. · 2020
Read Metformin and Its Benefits for Various Diseases. by Lv Z, Guo Y. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7212476.txt.
Introduction
Lv and Guo review the widening list of benefits claimed for metformin. Their article appeared in Frontiers in Endocrinology. Metformin has treated type 2 diabetes for over 60 years. It is a biguanide drug prized for safety and low cost. Its glucose-lowering power made it a first-line therapy worldwide.
Later research found effects far beyond blood sugar. Studies link it to lower risk in several cancers, from breast to colorectal. Obesity, liver disease, heart disease, and kidney disease also feature. Even aging itself is now discussed as a target. The drug acts through several signaling pathways. Which pathway drives which benefit is still unresolved. The review gathers the claims and the mechanisms proposed so far.
Catalog record
| CREATOR | Lv Z, Guo Y. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Metformin and Its Benefits for Various Diseases By Ziquan Lv, Yajie Guo Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2020.00191 ABSTRACT Abstract Metformin is a widely used biguanide drug due to its safety and low cost. It has been used for over 60 years to treat type 2 diabetes at the early stages because of its outstanding ability to decrease plasma glucose levels. Over time, different uses of metformin were discovered, and the benefits of metformin for various diseases and even aging were verified. These diseases include cancers (e.g., breast cancer, endometrial cancer, bone cancer, colorectal cancer, and melanoma), obesity, liver diseases, cardiovascular disease, and renal diseases. Metformin exerts different effects through different signaling pathways. However, the underlying mechanisms of these different benefits remain to be elucidated. The aim of this review is to provide a brief summary of the benefits of metformin and to discuss the possible underlying mechanisms. Keywords: metformin, benefits, diseases, mitochondrial respiratory chain complex I, AMPK INTRODUCTION Metformin, a derivative of biguanide, is one of the most commonly used drugs to treat type 2 diabetes (T2D), and it has been used for nearly one century (1). Guanidine was found to have anti-diabetic properties in animals in 1918, but unfortunately, it was toxic in clinical trials (2, 3). This prompted scientists to find safer substitutions. In the 1920s, metformin (1,1-dimethyl biguanide hydrochloride) was synthesized. Since then, metformin became the first choice to treat T2D due to its remarkable ability to decrease plasma glucose levels (3–5). In recent years, many additional unexpected but effective roles of metformin were found. Studies showed that metformin exerts a strong effect on numerous cancers (6, 7), cardiovascular disease (CVD) (8), liver diseases (9), obesity (10), neurodegenerative diseases (11), and renal diseases (12). Sole medication or combination therapy with other drugs has shown to be effective to treat different diseases. Metformin inhibits mitochondrial complex I (13, 14), which leads to AMPK (adenosine 5′- monophosphate—activated protein kinase) activation (15). Mitochondrial complex I is vital to electron transport. As a result, the production of ATP (adenosine triphosphate) decreases and the intracellular concentration of ADP (adenosine diphosphate) increases. Consequently, the cellular levels of AMP (adenosine monophpsphate) increases, finally activating AMPK (14, 16). Moreover, a recent study showed that metformin could activate AMPK via the lysosomal pathway, i.e., the AXIN/LKB1-v-ATPase-Regulator pathway (17). AMPK is a key regulator of numerous metabolic pathways, including glucose metabolism, lipid metabolism, and energy homeostasis (18, 19). Besides, metformin plays important roles by inhibiting insulin and IGF receptor signaling, resulting in changes in metabolic homeostasis (20). Recently, Using hdPCA (“homomer dynamics” protein-fragment complementation assays), a strategy that is able to map out gene functions and target pathways of drugs, it was found that the levels of proteins which were responsible for a broad set of cellular processes, including energy metabolism, aging, and cancer, were changed by metformin (21). The underlying mechanisms of metformin in the regulation of diseases, however, are still not fully understood. Here, we summarize the functions of metformin and discuss the underlying mechanisms from various perspectives, which may help to provide insight for future investigations. METFORMIN AND DIABETES Numerous studies and clinical trials have demonstrated that metformin monotherapy or combination therapy with other glucose-lowering drugs is effective in treating T2D. A report from 1995 illustrated that metformin is able to lower plasma glucose levels, and in the decades that followed, new roles of metformin in diabetes have been discovered. In the 1995 study, by Defronzo et al., 289 diabetes patients were treated with metformin or placebo. After 29 weeks, the metformin group showed lower mean fasting plasma glucose and HbA1c levels (22). In a 1997 study by Garber, 451 diabetic individuals were given different dosages of metformin (ranging from 500 mg to 2,000 mg daily). After 14 weeks, it was found that metformin's efficacy is dose-dependent (23). In 2006, a 5-year randomized and double blind clinical trial in which metformin was compared with glibenclamide and rosiglitazone, other anti-diabetic drugs, was published. The results showed that the fasting plasma glucose levels were decreased the least by rosiglitazone and the most by glibenclamide, with metformin showing intermediate effects (24). In some cases, metformin is used in combination with other anti-diabetic drugs or reagents. For example, in a 29-week study of 632 individuals, the combination of metformin and glibenclamide showed better glucose control than metformin alone (22). Glimepiride showed similar results in a clinical trial with 372 individuals (25). Another study showed that metformin and troglitazone lead to a stronger reduction in fasting plasma glucose and postprandial glucose levels after 3 months of treatment than treatment with metformin alone (26). Moreover, studies demonstrated that combination therapy of metformin with DPP4 inhibitors, SGLT2 inhibitors, or GLP1 receptor agonists also showed effective glucose control, without an additional risk of hypoglycaemia (27, 28). Combination of metformin and insulin is another way to treat diabetes. In a trial with 96 patients, this combination exhibited better control of glucose levels and weight gain than treatment with metformin alone (29). In another study, with 390 patients, the combination with insulin also exhibited better glucose control than treatment with metformin alone (30). Moreover, metformin improves insulin sensitivity and decreases fasting insulin levels in cognitive impairment patients with abnormal glucose metabolism (31). Metformin is a rational treatment choice for pregnant women with T2D, gestational diabetes (GDM), and polycystic ovarian syndrome (PCOS). Metformin was shown to have a stronger reducing effect on the body weight of PCOS patients than rosiglitazone. On the basis of in vitro and in vivo studies, including animal studies and clinical trials, the use of metformin in pregnancy is becoming increasing common globally (32). Nevertheless, the safety is controversial. Studies showed that children exposed to metformin may have a higher prevalence of obesity, BMI, abdominal fat volume, or blood pressure (33, 34). Other research suggested that patients taking metformin for more than 10 years had an increased risk of beta cell failure and insulin resistance (35). Although long follow-up studies may be required to explore the possible effects of metformin on human cells and tissues, metformin is undoubtedly the preferred treatment option for diabetes patients. Metformin exerts its anti-hyperglycemic effects mostly by suppressing hepatic glucose production through AMPK-dependent (36, 37) or -independent pathways (38, 39). On the one hand, metformin inhibits gluconeogenesis through AMPK-dependent activation of SHP (small heterodimer partner) and inhibition of phosphorylation of CBP (CREB binding protein) (40), thus suppressing the expression of gluconeogenic genes, such as G6Pase (glucose 6 phosphatase), PEPCK (phosphoenolpyruvate carboxykinase), and PC (pyruvate carboxylase) (41). Moreover, activation of AMPK leads to the inhibition of mTORC1 (mammalian target of rapamycin complex I), which also results in the suppression of gluconeogenesis (42). On the other hand, metformin inhibits hepatic glucose production in an AMPK-independent manner. Studies showed that metformin attenuates the ability of glucagon (43) or inhibits mitochondrial GPD (glycerol-3-phosphate dehydrogenase), subsequently leading to an impairment of lactate utilization for gluconeogenesis (39). Recently, a study also demonstrated that metformin directly targets FBP1 (fructose-1,6-bisphosphatase-1), the rate controlling enzyme in gluconeogenesis, inhibiting hepatic glucose production (44). Other studies suggested that metformin could also enhance GLUT1 (glucose transporter 1) mediated glucose transport into hepatocytes through activating IRS2 (insulin receptor substrate two), decreasing plasma glucose levels (45). Besides decreasing